article thumbnail

FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma

Drug Topics

A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.

article thumbnail

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

Pharmafile

The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Pharmacy Times

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

article thumbnail

New chemotherapy treatment could benefit multiple cancer types

European Pharmaceutical Review

A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This new guidance will clearly impact the clinical research field, but how?

article thumbnail

Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC

Pharmacy Times

Benefits throughout post-progression endpoints and outcomes were reported for osimertinib in combination with chemotherapy.

article thumbnail

Pembrolizumab plus chemotherapy improves overall survival compared to chemotherapy alone in advanced biliary tract cancer

Hospital Pharmacy Europe

Using pembrolizumab plus gemcitabine and cisplatin improves overall survival compared to chemotherapy alone in advanced biliary tract cancer Patients with biliary tract cancers invariably present at a late stage when curative surgery is not possible. Adults were randomised 1:1 to pembrolizumab plus chemotherapy or placebo and chemotherapy.